Wednesday, October 1, 2014 Last update: 5:03 PM
FreshNews.com - Tech News = Large & Small Companies (Many you've never heard of) Since 1996

Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference and New Directions in Biology and Disease of Skeletal Muscle Conference

Companies mentioned in this article: Catabasis Pharmaceuticals Inc.

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Catabasis Pharmaceuticals Inc. today announced that chief medical officer Joanne Donovan, M.D., Ph.D., will present an overview of CAT-1004, an oral small molecule designed to modulate NF-kB for the treatment of Duchenne Muscular Dystrophy (DMD), at the Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference in Chicago, IL, on June 28, 2014. In addition, Catabasis chief scientific officer and co-founder Michael Jirousek, Ph.D., will present at the 2014 New Directions in Biology and Disease of Skeletal Muscle Conference in Chicago, IL, on June 29, 2014.

Details of the presentations are as follows:

PPMD

  • Presenter: Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis
  • Date: Saturday, June 28, 11:20-11:40 a.m. CDT
  • Location: Chicago Marriott Downtown Magnificent Mile in Chicago, IL, Session 5

2014 New Directions in Biology and Disease of Skeletal Muscle Conference

  • Presenter: Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis
  • Date: Sunday, June 29, 2:00-3:00 p.m. CDT
  • Location: Chicago Marriott Downtown Magnificent Mile in Chicago, IL

About CAT-1004

CAT-1004 is a new chemical entity that modulates activated NF-kB, a central mediator of skeletal muscle inflammation. A growing body of evidence indicates that inflammation is a critical component of the underlying pathology of DMD and exacerbates muscle degeneration while inhibiting muscle regeneration. CAT-1004 modulates the NF-kB pathway by simultaneously inhibiting pro-inflammatory pathways and activating endogenous anti-inflammatory pathways to resolve inflammation. In preclinical models, CAT-1004 has been shown to reduce degenerating muscle tissue and increase regenerating muscle tissue while reducing muscle inflammation. In longer term preclinical DMD studies, CAT-1004 has been shown to improve muscle function. In early clinical studies, CAT-1004 has been shown to inhibit NF-kB activation and was safe and well-tolerated.

About Catabasis

Catabasis Pharmaceuticals is leveraging its pathway pharmacology drug development platform to bring important medicines to patients with severe lipid disorders and rare inflammatory diseases. The Company’s mission is to address difficult-to-treat diseases through the simultaneous modulation of multiple targets in a disease pathway. For more information on our technology and pipeline of drug candidates, please visit www.catabasis.com.


Copyright © Business Wire 2014
Contact:

Catabasis Pharmaceuticals Inc.
Amy Lynch, 617-349-1971
alynch@catabasis.com